In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery
- PMID: 37126816
- DOI: 10.7326/J23-0025
In outpatients with mild to moderate COVID-19, low-dose fluvoxamine did not reduce time to sustained recovery
Abstract
McCarthy MW, Naggie S, Boulware DR, et al. Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2023;329:296-305. 36633838.
Conflict of interest statement
Comment on
-
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.JAMA. 2023 Jan 24;329(4):296-305. doi: 10.1001/jama.2022.24100. JAMA. 2023. PMID: 36633838 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical